Chronic Pain Clinical Trial
Official title:
The Thrive Study: Improving Multimodal Physical Function in Adults With Heterogenous Chronic Pain: Multi-site Feasibility RCT
Verified date | March 2024 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators aim to conduct a randomized controlled trial to test the feasibility of a mind-body walking program compared to a health education program for individuals with chronic musculoskeletal pain. The investigators will assess the feasibility of recruitment procedures (enrollment, recruitment of racial and ethnic minorities) and intervention delivery (fidelity, adherence, credibility, satisfaction, optimization), following pre-specified benchmarks. Both programs will be delivered in-person.
Status | Active, not recruiting |
Enrollment | 90 |
Est. completion date | August 1, 2025 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male and female outpatients, age 18 years or older 2. Fluent in English 3. Have nonmalignant chronic musculoskeletal pain for more than 3 months 4. Able to perform a 6-minute walk test (6MWT) 5. Owns a smartphone with Bluetooth 4.0 or computer 6. Willingness and ability to participate in one of the 2 programs and to comply with the requirements of the study protocol. 7. Free of concurrent psychotropic medication for at least 2 weeks prior to initiation of treatment, OR stable on current medication for a minimum of 6 weeks and willing to maintain a stable dose 8. Low-level of activity (must meet 2/3 criteria; if difficult to assess, recruiter may ask participant to report their recent step data from their smartphone to better understand their activity level) 1. Sitting for more than 8 hours/day per self-report 2. Exercising for fewer than 3 days/week (30+min of exercise constitutes an "exercise day") per self-report 3. Walking for fewer than 7 days/week (30+min of walking constitutes a "walking day") per self-report Exclusion Criteria: 1. Diagnosed with a medical illness expected to worsen in the next 6 months (e.g., malignancy) 2. Serious mental illness or instability for which hospitalization may be likely in the next 6 months 3. Current active suicidal ideation reported on self-report 4. Untreated and/or unstable schizophrenia, bipolar disorder, or other psychotic disorder 5. Current, active substance abuse or dependence, and current alcohol dependence within the past 6 months 6. Practice of yoga, meditation, guided imagery or other mind body techniques that elicit the RR, once per week for >45 min 3 times/week within the last 3 months or less. 7. Regular use of Fitbit DMD in the last 3 months 8. Unable to walk/in a wheelchair 9. Mild cognitive decline for participants 65+ only (Short Portable Mental Status Questionnaire; PMSQ 4 or more errors). |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Rush Medical Center | Chicago | Illinois |
United States | Duke University | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | Duke University, National Center for Complementary and Integrative Health (NCCIH), Rush University Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment feasibility (ability) | Ability to enroll 80% or more of the sedentary chronic pain patients who meet study criteria. | 1 Year | |
Primary | Recruitment feasibility (timeliness) | Timeliness of enrollment; we will recruit a sample of 90 patients across the 3 sites over the course of 1 year. Participants will be considered enrolled upon attending Session 1. | 1 Year | |
Primary | Feasibility of recruitment racial and ethnic minorities | 38% or more of the entire sample will be comprised of racial and ethnic minorities, which is consistent with the current USA demographic distribution. | 1 Year | |
Primary | Intervention feasibility/ adherence to sessions | =80 chronic pain patients attend =7/10 sessions for each program (70%) | Post-Test (10 Weeks) | |
Primary | Credibility and Expectancy Scale | =80 chronic pain patients with credibility scores higher than the scale's mid point, indicating intervention credibility | Baseline (0 Weeks) | |
Primary | Client Satisfaction Scale | =80 chronic pain patients with credibility scores higher than the scale's mid point, indicating intervention satisfaction | Post-Test (10 Weeks) | |
Primary | Retention | =80 post-treatment, =75% 6 months follow up for self-report, performance based and Actigraph data (this includes valid data for all participants). | 1 Year | |
Primary | Assessment feasibility | =90 accuracy of standardized protocol checklists for all assessments. | 1 Year | |
Primary | Adherence to Accelerometer | Daily wear of charged ActiGraph GT9X for GetActive-Fitbit Daily wear of Actigraph accelerometer for baseline and follow-up assessments. | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | Pain, Enjoyment of Life and General Activity (PEG-3) Scale | Rate of a participant's pain intensity and related interference in enjoyment of life and general activity, using a 0-10 Likert scale | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | WHO Disability Assessment Schedule 2.0 (WHODAS) | The WHODAS measures level of functioning in six domains: cognition, mobility, self-care, getting along, life activities, and participation. Each question on the scale is measured 0-4, with higher scores indicating more disability. | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | 6 Minute Walk Test (6MWT) | The 6MWT is a performance-based measure that assesses physical function and endurance. | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | ActiGraph GT9X | The ActiGraph GT9X is a step count device that objectively measures function (number of steps). | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | PROMIS depression v1.08b | The PROMIS depression v1.08b measures negative mood, views of self and cognitions on a 5-point scale, with higher scores indicating more depressive symptoms | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | PROMIS anxiety v1.08a | The PROMIS anxiety v1.08a measures fear, worry, hyperarousal and somatic symptoms, with higher scores indicating more anxiety symptoms | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | Pain Catastrophizing Scale (PCS) | A 13-item questionnaire assessing one's tendency to focus on pain-related thoughts and feel helpless and hopeless due to pain on a scale of 0 to 4. Higher scores indicate higher pain catastrophizing | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | Tampa Kinesiophobia Scale (TSK) | A 17-item questionnaire that assesses fear avoidance and fear of activity. Higher scores indicate higher kinesiophobia | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | Measure of Current Status (MOCS) | The MOCS questionnaire assesses ability to engage in a series of healthy coping skills (e.g., relaxation, social support, adaptive thinking). Higher scores indicate a stronger ability to recognize stress and cope | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | Cognitive and Affective Mindfulness Scale (CAMS) | Rate of a participant's broad conceptualization of mindfulness, items range from 1-4. Higher values reflect higher levels of mindfulness | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) | |
Secondary | Modified Global Impression of Change (MGIC) | 2-item assessing the extent to which patients perceive the intervention improved functioning and symptoms. | Baseline (0 Weeks), Post-Test (10 Weeks), Follow-Up (24 Weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|